Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) (PRIDE)

This study has been completed.
Information provided by (Responsible Party):
Breathe Technologies, Inc. Identifier:
First received: May 17, 2011
Last updated: August 18, 2016
Last verified: August 2016
Results First Received: March 7, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Supportive Care
Conditions: Pulmonary Disease, Chronic Obstructive
Airflow Obstruction, Chronic
Chronic Obstructive Airway Disease
Chronic Obstructive Lung Disease
Intervention: Device: Noninvasive Open Ventilation System

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Noninvasive Open Ventilation System

Portable noninvasive open ventilator & nasal interface.

Noninvasive Open Ventilation System: Noninvasive ventilation system

Participant Flow:   Overall Study
    Noninvasive Open Ventilation System  
STARTED     22  
COMPLETED     18  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Adult subjects with chronic obstructive lung disease.

Reporting Groups
Noninvasive Open Ventilation System Portable noninvasive open ventilator & nasal interface. Noninvasive Open Ventilation System used during activities of daily living.

Baseline Measures
    Noninvasive Open Ventilation System  
Number of Participants  
[units: participants]
[units: participants]
<=18 years     0  
Between 18 and 65 years     5  
>=65 years     13  
[units: participants]
Female     9  
Male     9  
Race (NIH/OMB)  
[units: participants]
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     0  
White     18  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
United States     18  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Device Tidal Volume   [ Time Frame: Periodically over six hours x 5 days ]

2.  Secondary:   Device Preference   [ Time Frame: At conclusion of subject's participation (up to two weeks) ]

3.  Secondary:   Safety and Device-related Adverse Events   [ Time Frame: Continuous from Study Day 2 through Study Day 6 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Richard J. Morishige, MS, RRT
Organization: Clinical Research Consuting
phone: 510-606-0374

Responsible Party: Breathe Technologies, Inc. Identifier: NCT01355978     History of Changes
Other Study ID Numbers: CP-00-0031
Study First Received: May 17, 2011
Results First Received: March 7, 2015
Last Updated: August 18, 2016
Health Authority: United States: Institutional Review Board